Background {#Sec1}
==========

Developmental dysplasia of the hip (DDH) is a common disorder of hip deformity, with manifestations ranging from mild hip instability or acetabulum dysplasia to severe hip dislocation. Its reported incidence is 1.3--28.5 per 1000 infants per year \[[@CR1], [@CR2]\]. Delayed diagnosis and treatment of DDH may result in limping, hip pain, pelvic tilt, scoliosis and osteoarthritis. A proportion of 43% of end-stage osteoarthritis is associated with DDH \[[@CR3]\]. In Norway, DDH patients accounted for 9% in first-time total hip arthroplasty, and 29% of the patients treated with this procedure under 60 years of age also had DDH \[[@CR4]\]. Early diagnosis and treatment are critical to reduce risks of surgery and disability in patients with DDH. Ultrasonography examination is useful for the early diagnosis of DDH \[[@CR5]\].

The Pavlik harness is the most commonly used method for the treatment of DDH in infants aged 0--6 months \[[@CR6]\]. It allows a certain movement range of the hip and the knee while maintaining the hip joint in flexion and abduction, which is thought to promote the development of the femoral head and the acetabulum \[[@CR7]\]. The reported success rate of reduction in DDH using the Pavlik harness is around 70% \[[@CR8]--[@CR10]\]. A study comparing the Pavlik harness, the Craig splint and the von Rosen splint found that the rigid von Rosen splint was associated with significantly less avascular necrosis and reoperation than the Pavlik harness \[[@CR11]\]. The Tübingen splint is also a rigid splint and can maintain the flexion position of the hip while limiting its abduction \[[@CR12]\]. In this position, the pressure in the hip is distributed evenly with less vessel tension. This may reduce the incidence of avascular necrosis associated with the treatment of DDH.

Our study aimed to evaluate the efficacy and safety of the Tübingen hip flexion splints in treating DDH in infants aged 0--6 months.

Methods {#Sec2}
=======

This is a retrospective study analyzing the patients with DDH treated with the Tübingen hip flexion splints at our hospital between January 2015 and December 2017. Most of the patients were referred to our hospital from other cities. Only the Tübingen splint was used at our hospital. The inclusion criteria were as follows: Graf classification of type IIc, D, III and IV \[[@CR5]\]; diagnosed with DDH before the age of 6 months; no other treatment except the Tübingen splint; has been followed up for at least 6 months. Patients with the following conditions were excluded: hip dislocation caused by neuromuscular diseases; suppurative arthritis of the hip associated with dislocation; complicated with other skeletal or muscular diseases.

The parents were educated on the use of the Tübingen splint and how to use it at home. The patients were placed in the Tübingen splints with hip flexion of 90--110° and hip abduction of \< 60°. Patients with type IIc DDH wore the splints for at least 22 h daily with diaper changing and bathing if needed. Patients with type D, III or IV DDH wore the splints for 24 h daily and were evaluated every week. If the Graf classification was improved to type IIc or better, the splints were worn for at least 22 h daily with diaper changing and bathing if needed. Ultrasound examination was scheduled weekly for the first 3 weeks of treatment, then monthly until the 6th month of follow-up. Pelvic radiographs were taken at 6 months of age, the end of the treatment, 1 year of age, and 1.5--2 years of age. The splints were worn for an additional 1 month after normal ultrasound results of the hip. Then the treatment was stopped if ultrasound or pelvic radiography examination was normal.

Hip ultrasonography was classified using the Graf method \[[@CR5]\] (Table [1](#Tab1){ref-type="table"}). Hip radiography was classified according to the method proposed by the International Hip Dysplasia Institute (IHDI) \[[@CR13]\]. The presence of avascular necrosis of the femoral head was assessed according to the Bucholz-Ogden classification \[[@CR14]\]. Successful treatment was defined as an improvement of the Graft classification to type I, or an improvement of the IHDI classification to type I in patients older than 6 months without the need of open or closed reduction at the last follow-up. The treatment was deemed failure if the hip was not reduced after 3--4 weeks of treatment and required open or closed reduction. Table 1The Graf classification system of developmental dysplasia of the hip, based on sonographic angles of the hipTypeDescriptionBony RoofBony RimCartilage Roofα-angleβ-angleIMature hipGoodAngular/bluntCovers the femoral head≥60\< 77IIaPhysiological (\< 3 month)DeficientRoundedCovers the femoral head50--59\> 55IIbDelay of ossification (\> 3 month)DeficientRoundedCovers the femoral head50--59\< 55IIcCritical hipSeverely deficientRounded to flattenedStill covers the femoral head43--49\< 77DDecentering hipSeverely deficientRounded to flattenedDisplaced43--49\> 77IIIDislocated hipPoorFlattenedPressed upward, perichondrium slopes cranially\< 43\> 77IVDislocated hipPoorFlattenedPressed downward, perichondrium is horizontal or dips caudally\< 43

Continuous data were presented as means and standard deviations. Categorical data were presented as percentages or frequencies. Comparisons were made using the Student's *t*-test or the chi-square test. Risk factors of treatment failure were analyzed using the multivariate logistic regression model. Cut-off value of the age regarding treatment success or failure was calculated using the receiver operating characteristic (ROC) curve. *P* \< 0.05 was considered statistically significant.

Results {#Sec3}
=======

Patient general information {#Sec4}
---------------------------

A total of 193 infants (259 hips) were initially screen and 40 patients were excluded due to comorbidities (7 patients), lack of baseline ultrasonography (5 patients), uncooperative parents (1 patient) and incomplete follow-up data (27 patients). Finally, 153 patients (203 hips) were included in our study with 26 boys and 127 girls (Fig. [1](#Fig1){ref-type="fig"}). The mean age at diagnosis and treatment initiation was 8.6 ± 5.6 weeks (range, 1--29 weeks). DDH affected only the left side in 76 patients, only the right side in 27 patients, and bilaterally in 50 patients. The Graf classification of the hips is shown in Table [2](#Tab2){ref-type="table"}. The mean duration of treatment was 4.2 ± 2.2 months (range, 1--12 months). The mean follow-up time was 16.0 ± 7.7 months (range, 5--42 months). The treatment outcomes were considered successful in 128 patients (83.7%). Three patients (3 hips) with successful treatment were found to have mild avascular necrosis by radiography during follow-up 6 months after the treatment. Fig. 1Diagram of patient inclusionTable 2Graf classification of the 203 hips and their treatment outcomesGraf classificationSuccessful treatment (*n* = 165)Failed treatment (*n* = 38)*p*-valueIIc (%)79 (47.9)2 (5.3)\< 0.001D (%)46 (27.9)4 (10.5)0.035III (%)29 (17.6)6 (15.8)1IV (%)11 (6.7)26 (68.4)\< 0.001

Predictive factors and treatment outcomes {#Sec5}
-----------------------------------------

Comparison between infants with treatment success and those with treatment failures suggested that younger age at treatment initiation, unilateral hip involvement, no family history of DDH and Graf classifications \< type IV might predict successful treatment with the Tübingen splints (Table [3](#Tab3){ref-type="table"}). Multivariate logistic regression analysis suggested that age at treatment initiation, bilateral DDH and Graf classification were significantly associated with treatment outcomes (Table [4](#Tab4){ref-type="table"}). Sex, breech presentation, firstborn, swaddling, birth weight \> 3.5 kg, oligohydramnios, foot deformity and torticollis did not affect the success rate of treatment. The ROC curve showed that the cut-off value for age at treatment initiation regarding treatment success was 12 weeks, which yielded a sensitivity of 40% and a specificity of 88.3% (Fig. [2](#Fig2){ref-type="fig"}). The area under the ROC curve was 0.656 with a 95% confidence interval of 0.575--0.731. Table 3Comparison between DDH infants with treatment success and those with treatment failuresSuccessful treatment (*n* = 128)Failed treatment (*n* = 25)*p*-valueAge at treatment initiation, week8.0 ± 5.211.7 ± 6.60.020Male, n (%)23 (18)3 (12)0.663Unilateral DDH, n (%)91 (71.1)12 (48)0.024Family history of DDH, n (%)8 (6.3)7 (28)0.003Breech infant, n (%)27 (21.1)8 (32)0.235Swaddling, n (%)24 (18.7)8 (32)0.136First born, n (%)56 (43.8)15 (60)0.136Oligohydramnios, n (%)17 (13.3)2 (8)0.689Birth weight \> 3.5 kg, n (%)13 (10.2)0 (0)0.203Torticollis/foot deformity, n (%)7 (5.5)1 (4)1.000Graf type IV, n (%)7 (5.5)17 (68)\< 0.001*DDH* developmental dysplasia of the hipTable 4Risk factors of failure in Tübingen splint treatment for DDHCorrelation coefficientS.E.Wald*p*-valueOR95% CIAge at treatment initiation0.1110.0563.9420.0471.1181.001--1.247Gender1.0110.9591.1120.2922.7490.420--18.003Right side DDH0.8390.8960.8770.3492.3150.399--13.417Bilateral DDH1.7380.7485.3990.0205.6871.313--24.639Family history of DDH1.6280.8923.3360.0685.0960.888--29.250Graf classification3.6630.69427.873\< 0.00138.99310.008--151.927*DDH* developmental dysplasia of the hip, *OR* odds ratio, *CI* confidence intervalFig. 2The receiver operating characteristic curve of age at treatment initiation regarding successful treatment

The treatment failed in 25 patients (38 hips). Two patients (2 hips) had Graf type IIc DDH. One of them was treated with a Tübingen splint for 2 months starting from the age of 4 months. The treatment was stopped when ultrasonography was normal. Radiography at 1-year follow-up showed an IHDI type II. The patient was then managed with plaster casting. Another patient had Graf type IIc DDH on the right side and Graf type III DDH on the left side. Ultrasonography of the right hip was normal after 3 weeks of treatment. However, the left hip showed no improvement and was managed with plaster casting. Two patients (4 hips) had Graf type D DDH, which worsened to type III after 1 week and 3 weeks of treatment, respectively. They were also managed with plaster casting. Six patients had Graf type III DDH on one side and Graf type IV DDH on the opposite side. Three hips were improved to Graf type II after 3 weeks of treatment. However, the opposite sides showed no improvement and were managed with plaster casting. One hip worsened to Graf type IV at 2-week and 3-week follow-ups. Twenty-six hips of the 37 hips with Graf type IV DDH failed the treatment.

Case presentations {#Sec6}
------------------

### Case 1 {#Sec7}

A 17-week-old girl was referred to our hospital who was the firstborn with breech presentation and swaddling. Shen had bilateral developmental dysplasia of the hip of Graf classification type IV on the left side (Fig. [3](#Fig3){ref-type="fig"}a) and type III on the right side (Fig. [3](#Fig3){ref-type="fig"}b) shown by ultrasonography. The patient wore a Tübingen splint for 1 month. X-ray showed International Hip Dysplasia Institute type III one the left side and type II on the right side (Fig. [3](#Fig3){ref-type="fig"}c). Then closed reduction with casting of the hip was performed. However, avascular necrosis of the left femoral head was fond by radiography 1 month later (Fig. [3](#Fig3){ref-type="fig"}d). Fig. 3A 17-week-old girl who was the firstborn with breech presentation and swaddling

### Case 2 {#Sec8}

A 5-week-old girl was referred to our hospital with bilateral developmental dysplasia of the hip of Graf classification type IIa on the left side (Fig. [4](#Fig4){ref-type="fig"}a) and type D on the right side (Fig. [4](#Fig4){ref-type="fig"}b) shown by ultrasonography. She wore a Tübingen splint for 2 months. Radiography showed normal development in both hips (Fig. [4](#Fig4){ref-type="fig"}c). Fig. 4A 5-week-old girl with bilateral developmental dysplasia of the hips

### Case 3 {#Sec9}

A 5-week-old girl was referred to our hospital with bilateral developmental dysplasia of the hip of Graf classification type III on the left side (Fig. [5](#Fig5){ref-type="fig"}a) and type IIc on the right side (Fig. [5](#Fig5){ref-type="fig"}b) shown by ultrasonography. She wore a Tübingen splint for 3 months. Radiography showed normal development in both hips (Fig. [5](#Fig5){ref-type="fig"}c). Fig. 5A 5-week-old girl with bilateral developmental dysplasia of the hips

Discussion {#Sec10}
==========

Possible risk factors of DDH include family history of DDH, breech presentation, oligohydramnios, birth weight \> 3.5 kg, postterm pregnancy, firstborn baby and swaddling \[[@CR14], [@CR15]\]. In our study, 14/153 infants (9.2%) had family history of DDH and 6/14 of them (42.9%) failed the treatment. Our study showed that infants with family history of DDH had a significantly higher rate of treatment failure compared to those without family history. These findings support early screening of DDH if there is family history. In addition, many infants in our study had the following risk factors of DDH: breech presentation (23.5%), swaddling (20.9%), firstborn (47.1%), oligohydramnios (13.1%) and torticollis/foot deformity (5.9%). Our study did not find that these risk factors may affect the treatment outcomes of DDH using the Tübingen splint. However, infants with these risk factors should be screened for DDH.

In our study, the success rate of treating DDH of Graf type IIc and above before the age of 6 months using the Tübingen splint was 83.7%, which was comparable with previous studies (Table [5](#Tab5){ref-type="table"}) \[[@CR7], [@CR16], [@CR17], [@CR19], [@CR21]\]. Patient age at treatment initiation may influence treatment efficacy. Generally, older age at treatment initiation is associated with lower success rate of treatment. For example, Lin et al. \[[@CR21]\] reported a 67.4% of success rate with patients starting the treatment at an age of 14.3 weeks, which is older than the age of 8.6 weeks in our study. In addition, our results showed that patients with successful treatment started using the splint significantly earlier by nearly 1 month than those with treatment failures. Older age of the infants promotes the maturity of the hip and reduce the bone plasticity required for successful splint treatment. Therefore, early screening in infants at increased risks of DDH and early treatment are critical for good outcomes. Unfortunately, DDH screening is still not a routine examination in China. Most of our patients were referred from other cities with probably delayed diagnosis. Table 5Summary of literatures for treating developmental dysplasia of the hip using the Tübingen splintYearAuthorPatients (hips)Age at treatment initiation (day)Graf classificationSuccessFailureSuccess rateAvascular necrosis2012T. Seidl \[[@CR16]\]42 (50)3.5IIc6049/50 (98%)0D330III100IV012013Bayalag Munkhuu \[[@CR17]\]99 (120)1.9IIc35195/97 (98%)0D700III141IV----2014Hakan Atalar \[[@CR18]\]49 (60)126IIb19056/60 (93.3%)0IIc243D10III111IV102014Vito Pavone \[[@CR19]\]351 (554)39IIb----92.3%3IIc----D----III----IV----2017Hannes Kubo \[[@CR7]\]79 (109)\< 42D510104/109 (95.4%)III451IV842018Murat Yegen \[[@CR20]\]92 (104)83IIc----78 (75%)0D----III----IV----2019Lin Ran \[[@CR21]\]34 (43)100IIb18029/43 (67.4%)0IIc73D00III10IV311

Another affecting factor of treatment outcome of the Tübingen splint in DDH is disease severity. A previous multicenter prospective study showed a high treatment failure rate in patients with Graf type IV DDH \[[@CR22]\]. The treatment failure rate for Graf IV DDH was 33.3% (4/12) and 78.6% (11/14) in two previous studies \[[@CR7], [@CR21]\]. In our study, the treatment failure rate in the Graf type IV hips was significantly higher than other Graf types (70.3% vs 7.2%, *p* \< 0.001). The Tübingen splint is a rigid brace, which is different from the non-rigid Pavlik harness and is not capable of reducing severe hip dislocations. Reduction before wearing the Tübingen splint may be a possible technique to increase the success rate of hip reduction. However, this suggestion still needs clinical evidence.

Avascular necrosis of the femoral head is the most important complication in treating DDH. The reported incidence of avascular necrosis in DDH treated with the Pavlik harness was 0--30% \[[@CR10], [@CR23]\]. On the contrary, treating DDH with the Tübingen splint was found to be associated with relatively lower incidence of avascular necrosis \[[@CR18]--[@CR20]\]. In our study, 3 patients (2.0%) with 3 hips (1.5%) achieved successful treatment outcomes but were found to have mild avascular necrosis by follow-up radiography according to the Bucholz-Ogden classification. The relatively high incidence of avascular necrosis of the Pavlik harness may be attributed to the over abduction of the hip, which is associated with the non-rigid design of this orthosis. The rigid Tübingen splint can effectively limit the abduction of the hip and possibly reduce the incidence of avascular necrosis.

There are limitations in our study. Our study is a single-center retrospective study and lakes baseline physical examinations. Reducible and irreducible hip dislocations were indiscriminately included. The Tübingen splints were worn with varied time periods ranging from 20 to 24 h daily. Hip reduction was not required before treatment initiation. A high proportion of 17.7% of the patients were lost to follow-up. The short follow-up time may not reveal the true incidence of avascular necrosis. The ultrasonography was only viewed by a single specialist, which may give inaccurate diagnoses.

Conclusions {#Sec11}
===========

The Tübingen splints showed good efficacy in treating DDH in infants aged 0--6 months with low risks of avascular necrosis of the femoral head. Family history of DDH, Graf classification of type IV, bilateral involvement and treatment initiation after 12 weeks of age may predict treatment failure. The Tübingen splint is a sensible option for treating DDH besides the Pavlik harness.

DDH

:   Developmental dysplasia of the hip

IHDI

:   The International Hip Dysplasia Institute

ROC

:   The receiver operating characteristic
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